Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion
Emmanuel Martinod, Paulina Kuczma, Christophe Trésallet, Cécile Ghander, Camille Buffet, Eric Vicaut · 2025
Read Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion by Emmanuel Martinod, Paulina Kuczma, Christophe Trésallet, Cécile Ghander, Camille Buffet, Eric Vicaut (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742051.txt.
Description
Emmanuel Martinod and five co-authors write in support of a drug-first strategy for thyroid cancers choking the airway, in a 2025 letter. They comment on a study by Katoh and colleagues of lenvatinib, a targeted drug, used urgently in advanced thyroid cancer invading the windpipe and voice box.
In that study of 14 patients with severe invasion, the drug shrank tumors fast and widened airways in nearly all cases, easing symptoms within days. Only one patient developed a controlled fistula. The letter writers endorse the approach as a fast, non-surgical bridge that can spare patients emergency airway operations. Their endorsement adds surgical voices to a strategy that changes who must be rushed to the operating room.
Catalog record
| CREATOR | Emmanuel Martinod, Paulina Kuczma, Christophe Trésallet, Cécile Ghander, Camille Buffet, Eric Vicaut |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |